Merck's antiviral drug meets main goal in late-stage trial

Merck's antiviral drug meets main goal in late-stage trial


Oct 19 Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial. Cytomegalovirus is a member of the herpes virus family and remains a significant cause of viral infections in transplant recipients.



from Biotech News